Company Overview
Snapshot
Founded in November 2020 by Dana Cohen, Liora Madar Shapiro, and Tal Peleg-Shulman, BioMe operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on research and development.
Business overview
BioMe offers a platform for personal microbiome processing, restoration, storage, and analytics within the Health Tech & Life Sciences sector. The company's core technology involves safe, dry, and odor-free microbiome capsules designed for healthy adults. These self-microbiome capsules aim to accelerate the natural restoration of gut microbiota, which can be eradicated by various medical treatments such as antibiotics, antidepressants, laxatives, and chemotherapy. BioMe serves markets in North America and Asia, operating within the broader Pharmaceuticals and Precision Medicine categories.
Log in to access full profile ›Company Intelligence Q&A
- When was BioMe founded and by whom?
- BioMe was founded in November 2020 by co-founders Dana Cohen, Liora Madar Shapiro, and Tal Peleg-Shulman.
- What is BioMe's primary focus in the healthcare industry?
- BioMe focuses on microbiome restoration and analytics, providing a platform for processing, storing, and analyzing personal microbiomes to accelerate the natural restoration of gut microbiota.
- What product does BioMe offer?
- BioMe offers safe, dry, and odor-free microbiome capsules for healthy adults, designed to help restore gut microbiota commonly affected by medications like antibiotics and chemotherapy.
- Which markets does BioMe target?
- BioMe targets geomarkets in North America and Asia.
- What is BioMe's current stage of development?
- BioMe is currently in the Pre-Funding stage, with its products in the R&D phase.